Novo Nordisk Shares Fall

Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results
The pharmaceutical giant released fresh trial data showing the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight.
Novo Nordisk shares fall 5.4% after latest trial results for its next-generation weight loss drug
Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.
Novo Nordisk says trial with next-gen drug in diabetics shows 15.7% weight loss
Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 diabetes cut their weight by 15.7% after 68 weeks.
Novo Nordisk's CagriSema Trial Results Fall Short, Market Reacts
Novo Nordisk's obesity drug CagriSema failed to outperform Eli Lilly's Mounjaro in the latest trial, causing a dip in Novo's market shares. The trial showed a 13.7% weight loss, which fell short of expectations.
Novo Nordisk's CagriSema data disappoints investors again
Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline weight-loss result has sent its shares into a sharp decline.
Novo Nordisk down 6% after results for trial of weight-loss drug CagriSema
Shares of Novo Nordisk (NVO) trading in New York are down $5.22, or 6%, to $81.95 in the pre-market session.Discover the Best Stocks and
Novo Nordisk plunges following latest CagriSema data
Investing.com -- Novo Nordisk’s stock has dropped around 6.6% in premarket trading Monday following the release of its latest clinical trial data for CagriSema, a treatment for adults with obesity or overweight and type 2 diabetes.
Novo Nordisk to explore how GLP-1 drugs can help patients with addiction
Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst Lange told an online press conference on Thursday.
Novo Nordisk's CagriSema: A Breakthrough in Obesity Treatment for Diabetics
Novo Nordisk's experimental drug, CagriSema, demonstrated a 15.7% weight reduction in obese individuals with type 2 diabetes over 68 weeks. Key findings from the phase III REDEFINE 2 trial highlight its potential,
Novo Nordisk stock falls on trial results
Investing.com -- Shares of Novo Nordisk (NYSE: NVO) tumbled 6% today, following the announcement of results from its REDEFINE 2 phase 3 trial. Despite meeting its primary endpoint, showing statistically significant weight loss with its CagriSema treatment compared to placebo, the market reacted negatively.
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial
Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial investigating
Novo Nordisk slashes Wegovy price for patients lacking insurance benefits
Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...
Fierce Pharma2d
With blood and growth disorder bids panning out, Novo Nordisk plots path to rare disease leadership: exec
Still, Novo is steadfast in its goal to eventually become a leader in the space, the company’s EVP of rare disease, Ludovic ...
Novo Nordisk (NVO) Warns of Drug Shortages if Tariffs Are Imposed
Novo Nordisk (NVO), the company behind popular diabetes and weight loss medications Ozempic and Wegovy, warned that President ...